Contineum Therapeutics Reports $12.8 Million Net Loss in Q3 2025

Contineum Therapeutics, Inc. reported a net loss of $12.8 million for the third quarter of 2025, compared to a loss of $10.3 million in the same period of the previous year. For the nine months ending September 30, 2025, the company recorded a net loss of $44.8 million, up from $27.7 million in the prior year. Operating expenses for the third quarter increased to $14.9 million from $13.0 million year-over-year, driven primarily by higher research and development costs, which rose to $11.0 million from $9.7 million. The increase in R&D expenses was attributed to higher personnel costs and increased spending on clinical trials, particularly for the company's lead drug candidates, PIPE-791 and PIPE-307.

In terms of financial position, Contineum's total assets decreased to $190.8 million as of September 30, 2025, down from $212.8 million at the end of 2024. The decline was primarily due to a reduction in marketable securities, which fell to $139.8 million from $182.8 million. The company’s cash and cash equivalents increased to $42.6 million, up from $21.9 million at the end of 2024, reflecting proceeds from an at-the-market offering where 3.2 million shares were sold at an average price of $6.04, generating approximately $19.0 million in net proceeds.

Contineum has made significant strides in its clinical development pipeline, particularly with PIPE-307, which is being developed in collaboration with Johnson & Johnson. The company has completed enrollment for a Phase 2 trial of PIPE-307 for the treatment of relapse-remitting multiple sclerosis and expects to report topline data in the fourth quarter of 2025. Additionally, the company is preparing to initiate a global Phase 2 trial for PIPE-791 in idiopathic pulmonary fibrosis by the end of 2025. The collaboration with J&J includes potential milestone payments totaling approximately $1 billion, along with tiered royalties on net sales.

As of September 30, 2025, Contineum had an accumulated deficit of $162.2 million, reflecting its ongoing investment in research and development. The company anticipates that its operating expenses will continue to rise as it advances its clinical trials and expands its operations. Management believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months. However, the company may seek additional financing through public or private equity sales, debt financing, or strategic partnerships to support its ongoing development efforts.